Although there is well established association between JAK2 positive MPN and thrombotic events, pre‐hepatic portal hypertension presenting with complications such as ascites, SBP and splenomegaly are infrequently evaluated for JAK2 mutations. Here, JAK2 is linked to myeloproliferative disorder.